サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1433434

薬剤溶出ステントの世界市場：2023-2030年

Global Drug-Eluting Stent Market 2023-2030
出版日: | 発行: Orion Market Research | ページ情報: 英文 105 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
薬剤溶出ステントの世界市場：2023-2030年
出版日: 2024年01月04日
発行: Orion Market Research
ページ情報: 英文 105 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の薬剤溶出ステント市場は、予測期間（2023-2030年）にCAGR 7.6％で成長すると予測されています。市場成長の主な要因としては、高齢者人口の増加、心血管疾患（末梢動脈疾患および冠動脈疾患）の有病率の増加、有利な政府の取り組みや政策、新しく強化された技術製品の導入などが挙げられます。米国心臓協会（AHA）は「末梢動脈疾患における健康格差」という論文を発表しました。それによると、末梢動脈疾患（PAD）は世界で2億人が罹患しています。米国では、特定の人口集団がPADの有病率と臨床的影響を不釣り合いに高めています。PADの社会的・臨床的影響には、心血管系および脳血管系イベントとともに、身体障害、うつ病、小・大肢切断の高い割合が含まれます。

セグメント別の展望

薬剤溶出ステントの世界市場では、冠動脈ステントのサブセグメントが大きなシェアを占めると予想されます。

用途別では、冠動脈ステント留置サブセグメントが予測期間中に成長すると予測されています。このセグメントの成長の背景には、冠動脈疾患（CAD）の罹患率の増加、技術の進歩、政府の結束した政策があります。CVDの中でもCADの有病率は最も高いです。2023年1月に発表された英国心臓財団（BHF）のデータによると、2021年に最も一般的な心血管疾患は冠動脈（虚血性）心疾患（2019年の世界有病率は2億人と推定）、末梢動脈（血管）疾患（1億1,000万人）、脳卒中（1億人）、心房細動（6,000万人）であると報告されています。さらに、北米における心臓・循環器疾患の有病率は4,800万人、欧州では1億人、アフリカ・中東では9,800万人、ラテンアメリカでは4,800万人、アジア・オーストラリアでは3億4,000万人であることが明らかになった。

地域別展望

世界薬剤溶出ステント市場は、北米（米国、カナダ）、欧州（英国、イタリア、スペイン、ドイツ、フランス、そ他欧州地域）、アジア太平洋地域（インド、中国、日本、韓国、そ他アジア地域）、世界そ他地域（中東とアフリカ、ラテンアメリカ）など、地域別にさらに細分化されています。中でも欧州は、高齢者人口増加、冠動脈疾患有病率増加、医療費増加により、予測期間中に成長すると予測され、欧州の薬剤溶出ステント市場を牽引しています。

薬剤溶出ステントの世界市場では北米地域がCAGRで大きく成長する見込み

予測期間中、薬剤溶出ステント市場では北米が大きなシェアを占めると予想されています。高齢者人口増加に伴い、動脈疾患へ傾向が強まっており、薬剤溶出ステントなどより効果的な治療ソリューションが必要とされています。動脈にプラークが増加する動脈硬化有病率も、座りがちなライフスタイルや食生活乱れによって急増しています。米国国立衛生研究所（NIH）が発表した調査報告によると、2020年3月、米国の成人動脈硬化性心血管疾患（ASCVD）有病率は1,830万人（8.0％）です。この疾患は、心臓発作や脳卒中を含む様々な心血管系疾患に大きく関与しています。このような健康上懸念高まりを受けて、医療関係者間では、動脈硬化に対する好ましい治療法として薬剤溶出ステントへ注目が高まっています。米国心臓協会によると、米国における2020年CVDに起因する死亡原因第1位（41.2％）は冠動脈性心疾患（CHD）であり、脳卒中（17.3％）、そ他CVD（16.8％）、高血圧（12.9％）、心不全（9.2％）がこれに続きます。米国の成人におけるアテローム性動脈硬化性心血管疾患（ASCVD）有病率は1,830万人（8.0％）です。690,524人成人が昨年急性冠症候群を発症しており、600万人以上が非常に危険な状態になっています。

目次

第1章 レポート概要

  • 業界の現状分析と成長ポテンシャルの展望
  • 調査方法とツール
  • 市場内訳
    • セグメント別
    • 地域別

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向
    • 主な調査結果
    • 推奨事項
    • 結論

第3章 競合情勢

  • 主要企業分析
  • Abbott Laboratories
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Boston Scientific Corp.
    • 会社概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Biotronik SE & Co. KG
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Medtronic Plc
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Terumo Corp.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • 主要戦略分析

第4章 市場セグメンテーション

  • 薬剤溶出ステントの世界市場：材料別
    • ステンレス鋼
    • コバルトクロム合金
    • その他（白金-クロム合金）
  • 薬剤溶出ステントの世界市場：タイプ別
    • 永久
    • 生分解性
  • 薬剤溶出ステントの世界市場：用途別
    • 冠動脈ステント留置術
    • 末梢動脈ステント
  • 薬剤溶出ステントの世界市場：エンドユーザー別
    • 病院
    • 心臓カテーテル検査室

第5章 地域別分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 世界のその他の地域

第6章 企業プロファイル

  • Alvimedica SA
  • B. Braun SE
  • Biosensors International Group, Ltd.
  • Cardionovum GmbH
  • Cook Group Inc.
  • Elixir Medical Corp.
  • Hexacath
  • InspireMD Inc.
  • JW Medical Systems LTD.
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • MicroPort Scientific Corp.,
  • OrbusNeich Medical Co. Group Holdings Ltd.
  • Sino Medical Sciences Technology Inc.
  • Translumina GmbH
  • Vascular Concepts Ltd.
図表

LIST OF TABLES

  • 1. GLOBAL DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY MATERIAL, 2023-2031 ($ MILLION)
  • 2. GLOBAL DRUG-ELUTING STENT OF STAINLESS-STEEL MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 3. GLOBAL DRUG-ELUTING STENT OF COBALT-CHROMIUM ALLOY MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 4. GLOBAL DRUG-ELUTING STENT OF OTHER MATERIALS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 5. GLOBAL DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2023-2031 ($ MILLION)
  • 6. GLOBAL PERMANENT DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 7. GLOBAL BIODEGRADABLE DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 8. GLOBAL DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2023-2031 ($ MILLION)
  • 9. GLOBAL DRUG-ELUTING STENT FOR CORONARY ARTERY STENTING MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 10. GLOBAL DRUG-ELUTING STENT FOR PERIPHERAL ARTERY STENTING MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 11. GLOBAL DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY END-USERS, 2023-2031 ($ MILLION)
  • 12. GLOBAL DRUG-ELUTING STENT FOR HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 13. GLOBAL DRUG-ELUTING STENT FOR CARDIAC CATHETERIZATION LABORATORIES MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 14. GLOBAL DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 15. NORTH AMERICAN DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
  • 16. NORTH AMERICAN DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY MATERIAL, 2023-2031 ($ MILLION)
  • 17. NORTH AMERICAN DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2023-2031 ($ MILLION)
  • 18. NORTH AMERICAN DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2023-2031 ($ MILLION)
  • 19. NORTH AMERICAN DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY END-USERS, 2023-2031 ($ MILLION)
  • 20. EUROPEAN DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
  • 21. EUROPEAN DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY MATERIAL, 2023-2031 ($ MILLION)
  • 22. EUROPEAN DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2023-2031 ($ MILLION)
  • 23. EUROPEAN DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2023-2031 ($ MILLION)
  • 24. EUROPEAN DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY END-USERS, 2023-2031 ($ MILLION)
  • 25. ASIA-PACIFIC DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
  • 26. ASIA-PACIFIC DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY MATERIAL, 2023-2031 ($ MILLION)
  • 27. ASIA-PACIFIC DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2023-2031 ($ MILLION)
  • 28. ASIA-PACIFIC DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2023-2031 ($ MILLION)
  • 29. ASIA-PACIFIC DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY END-USERS, 2023-2031 ($ MILLION)
  • 30. REST OF THE WORLD DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 31. REST OF THE WORLD DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY MATERIAL, 2023-2031 ($ MILLION)
  • 32. REST OF THE WORLD DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2023-2031 ($ MILLION)
  • 33. REST OF THE WORLD DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2023-2031 ($ MILLION)
  • 34. REST OF THE WORLD DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY END-USERS, 2023-2031 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL DRUG-ELUTING STENT MARKET SHARE BY MATERIAL, 2023 VS 2031 (%)
  • 2. GLOBAL DRUG-ELUTING STENT OF STAINLESS-STEEL MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 3. GLOBAL DRUG-ELUTING STENT OF COBALT-CHROMIUM ALLOY MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 4. GLOBAL DRUG-ELUTING STENT OF OTHER MATERIALS MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 5. GLOBAL DRUG-ELUTING STENT MARKET SHARE BY TYPE, 2023 VS 2031 (%)
  • 6. GLOBAL PERMANENT DRUG-ELUTING STENT MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 7. GLOBAL BIODEGRADABLE DRUG-ELUTING STENT MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 8. GLOBAL DRUG-ELUTING STENT MARKET SHARE BY APPLICATION, 2023 VS 2031 (%)
  • 9. GLOBAL DRUG-ELUTING STENT FOR CORONARY ARTERY STENTING MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 10. GLOBAL DRUG-ELUTING STENT FOR PERIPHERAL ARTERY STENTING MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 11. GLOBAL DRUG-ELUTING STENT MARKET RESEARCH AND ANALYSIS BY END-USERS, 2023 VS 2031 (%)
  • 12. GLOBAL DRUG-ELUTING STENT FOR HOSPITALS MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 13. GLOBAL DRUG-ELUTING STENT FOR CARDIAC CATHETERIZATION LABORATORIES MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 14. GLOBAL DRUG-ELUTING STENT MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 15. US DRUG-ELUTING STENT MARKET SIZE, 2023-2031 ($ MILLION)
  • 16. CANADA DRUG-ELUTING STENT MARKET SIZE, 2023-2031 ($ MILLION)
  • 17. UK DRUG-ELUTING STENT MARKET SIZE, 2023-2031 ($ MILLION)
  • 18. FRANCE DRUG-ELUTING STENT MARKET SIZE, 2023-2031 ($ MILLION)
  • 19. GERMANY DRUG-ELUTING STENT MARKET SIZE, 2023-2031 ($ MILLION)
  • 20. ITALY DRUG-ELUTING STENT MARKET SIZE, 2023-2031 ($ MILLION)
  • 21. SPAIN DRUG-ELUTING STENT MARKET SIZE, 2023-2031 ($ MILLION)
  • 22. REST OF EUROPE DRUG-ELUTING STENT MARKET SIZE, 2023-2031 ($ MILLION)
  • 23. INDIA DRUG-ELUTING STENT MARKET SIZE, 2023-2031 ($ MILLION)
  • 24. CHINA DRUG-ELUTING STENT MARKET SIZE, 2023-2031 ($ MILLION)
  • 25. JAPAN DRUG-ELUTING STENT MARKET SIZE, 2023-2031 ($ MILLION)
  • 26. SOUTH KOREA DRUG-ELUTING STENT MARKET SIZE, 2023-2031 ($ MILLION)
  • 27. REST OF ASIA-PACIFIC DRUG-ELUTING STENT MARKET SIZE, 2023-2031 ($ MILLION)
  • 28. REST OF THE WORLD DRUG-ELUTING STENT MARKET SIZE, 2023-2031 ($ MILLION)
目次
Product Code: OMR2028102

Global Drug-eluting Stent Market Size, Share & Trends Analysis Report by material (Stainless Steel, Cobalt-Chromium Alloy, and Others), By Type, (Permanent and Biodegradable), By Application (Coronary Artery Stenting and Peripheral Artery Stenting), and by End-User (Hospitals and Cardiac Catheterization Laboratories), Forecast Period (2024-2031)

The global drug-eluting stent market is anticipated to grow at a CAGR of 7.6% during the forecast period (2023-2030). Some of the major factors attributed to the market growth include the rising geriatric population, increasing prevalence of cardiovascular diseases (peripheral and coronary artery diseases), favorable government initiatives and policies, and the introduction of new and enhanced technological products. The American Heart Association (AHA) published an article called "Health Disparities in Peripheral Artery Disease": A Scientific Statement from the AHA, according to which peripheral artery disease (PAD) affects 200 million individuals globally. In the US, certain demographic groups experience a disproportionately higher prevalence and clinical effect of PAD. The social and clinical effect of PAD includes higher rates of individual disability, depression, minor and major limb amputation along with cardiovascular and cerebrovascular events.

Segmental Outlook

The global drug-eluting stent market is segmented by material, product, type, application, and end-users. Based on the material, the market is sub-segmented into stainless steel, cobalt-chromium alloy, and others. Others include platinum-chromium alloy. Based on the type, the market is sub-segmented into permanent, and biodegradable. Based on the application, the market is divided into coronary artery stenting and peripheral artery stenting. Further, based on end-users, the market is sub-segmented into hospitals and cardiac catheterization laboratories. Among the end-users, the hospitals sub-segment is anticipated to hold the largest market share during the forecast period, owing to the lower costs, higher efficiency, and availability.

The Coronary Artery Stenting Sub-Segment is Anticipated to Hold a Considerable Share of the Global Drug-Eluting Stent Market

Among the applications, the coronary artery stenting sub-segment is expected to grow over the forecast period. Segmental growth is attributed to the increasing incidence of coronary artery diseases (CAD), technological advancements, and cohesive government policies. Among all CVDs, CAD has the highest prevalence. The British Heart Foundation (BHF) data published in January 2023 reported that in 2021, the most common cardiovascular conditions are coronary (ischemic) heart disease (global prevalence estimated at 200 million in 2019), peripheral arterial (vascular) disease (110 million), stroke (100 million) and atrial fibrillation (60 million). Additionally, the report revealed that the prevalence of heart and circulatory diseases in North America was 48 million, in Europe it was 100 million, in Africa and the Middle East it was 98 million, in Latin America it was 48 million, and in Asia and Australia it was 340 million.

Regional Outlook

The global drug-eluting stent market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Europe is anticipated to grow over the forecast period, owing to the increasing geriatric population, increasing prevalence of coronary artery diseases the rising healthcare expenditure, driving the drug-eluting stent market in Europe.

The North American region is Expected to Grow at a Significant CAGR in the Global Drug-eluting Stent Market

North America is expected to hold a prominent share in the Drug-eluting Stent market during the forecast period. With the rising elderly population, there is an increased inclination to arterial diseases, requiring more effective treatment solutions such as drug-eluting stents. The prevalence of atherosclerosis, marked by the increase of plaque in arteries, has also surged owing to sedentary lifestyles and poor dietary choices. According to research reports published by the National Institutes of Health (NIH), in March 2020, the prevalence of atherosclerotic cardiovascular disease (ASCVD) among adults in the US is 18.3 million (8.0%). This condition significantly contributes to various cardiovascular diseases, including heart attacks and strokes. In response to this mounting health concern, medical professionals are increasingly turning to drug-eluting stents as a preferred treatment for atherosclerosis. According to the American Heart Association, in 2020 in the US, coronary heart disease (CHD) was the leading cause (41.2%) of deaths attributable to CVD in the US, followed by stroke (17.3%), other CVD (16.8%), high blood pressure (12.9%), and heart failure (9.2%). The prevalence of atherosclerotic cardiovascular disease (ASCVD) amongst adults in the US is 18.3 million (8.0%). 690,524 adults had an acute coronary syndrome event last year, and over 6 million are at very high risk.

Market Players Outlook

The major companies serving the drug-eluting stent market include Abbott Laboratories, Boston Scientific Corp., Biotronik SE & Co. KG, Medtronic Plc, Terumo Corp., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in May 2023, CoSo Health signed a US distribution agreement with Medinol for EluNIR™, a new generation, thin-strut drug-eluting stent (DES). Medinol is a pioneer in the development of implantable medical devices.

The Report Covers:

  • Market value data analysis of 2023 and forecast to 2031.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global drug-eluting stent market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Abbott Laboratories
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Boston Scientific Corp.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Biotronik SE & Co. KG
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Medtronic Plc
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. Terumo Corp.
    • 3.6.1. Overview
    • 3.6.2. Financial Analysis
    • 3.6.3. SWOT Analysis
    • 3.6.4. Recent Developments
  • 3.7. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Drug-Eluting Stent Market by Material
    • 4.1.1. Stainless Steel
    • 4.1.2. Cobalt-Chromium Alloy
    • 4.1.3. Others (Platinum-Chromium Alloy)
  • 4.2. Global Drug-Eluting Stent Market by Type
    • 4.2.1. Permanent
    • 4.2.2. Biodegradable
  • 4.3. Global Drug-Eluting Stent Market by Application
    • 4.3.1. Coronary Artery Stenting
    • 4.3.2. Peripheral Artery Stenting
  • 4.4. Global Drug-eluting Stent Market by End-User
    • 4.4.1. Hospitals
    • 4.4.2. Cardiac Catheterization Laboratories

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Alvimedica SA
  • 6.2. B. Braun SE
  • 6.3. Biosensors International Group, Ltd.
  • 6.4. Cardionovum GmbH
  • 6.5. Cook Group Inc.
  • 6.6. Elixir Medical Corp.
  • 6.7. Hexacath
  • 6.8. InspireMD Inc.
  • 6.9. JW Medical Systems LTD.
  • 6.10. Lepu Medical Technology (Beijing) Co., Ltd.
  • 6.11. MicroPort Scientific Corp.,
  • 6.12. OrbusNeich Medical Co. Group Holdings Ltd.
  • 6.13. Sino Medical Sciences Technology Inc.
  • 6.14. Translumina GmbH
  • 6.15. Vascular Concepts Ltd.